Skip to main content
. Author manuscript; available in PMC: 2023 Feb 1.
Published in final edited form as: Ann Intern Med. 2022 Jul 12;175(8):1083–1091. doi: 10.7326/M21-3846

Table 3.

Effect Estimates of HCV Cure on All-Cause Mortality and Non–Drug-Related or Non–Trauma-Related Mortality

Effect Estimate Undetectable HCV RNA Detectable HCV RNA
All-cause mortality
 Unadjusted hazard ratio (95% CI) 0.42 (0.30–0.59) Reference
 IPTW-adjusted hazard ratio (95% CI)* 0.54 (0.38–0.77) Reference
Non–drug-related or non–trauma-related mortality
 Unadjusted hazard ratio (95% CI) 0.32 (0.21–0.50) Reference
 IPTW-adjusted hazard ratio (95% CI)* 0.41 (0.26–0.64) Reference

AUDIT = Alcohol Use Disorders Identification Test; BMI = body mass index; HCV = hepatitis C virus; IPTW = inverse probability treatment weight; LSM = liver stiffness measure.

*

IPTWs were calculated using race, sex, recruitment cohort, age, AUDIT category, injection drug use in the previous 6 months, methadone use in the previous 6 months, BMI, number of comorbidities, HIV status, lagged HCV RNA status (previous visit), lagged LSM ≥12.3 kPa, lagged AUDIT category, lagged injection drug use in the previous 6 months, lagged methadone use in the previous 6 months, and lagged BMI.